Sormani MP, Häring DA, Kropshofe H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, #277.
Besluit sluisgeneesmiddel ravulizumab (Ultomiris)
apr 2024 | Neuro-musculair
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen
aug 2021 | Hoofdpijn